Site Editor

Al B. Benson III, MD, FACP, FASCO

Advertisement
Advertisement

Changing Trends in Incidence and Survival in Patients With Intrahepatic Cholangiocarcinoma

By: Joshua Swore, PhD
Posted: Friday, September 30, 2022

Statistics associated with intrahepatic cholangiocarcinoma have been changing since 2000, according to an article published in Annals of Hepato-Biliary-Pancreatic Surgery, with a continued increase in the rates of this type of liver cancer, particularly in older individuals. “Our results report the latest incidence and survival across a comprehensive age continuum for the first time,” explained Hassam Ali, MD, of East Carolina University, North Carolina, and colleagues. “They suggest periods of increased mortality and incident risk of [intrahepatic cholangiocarcinomas] in the United States.” In fact, the investigators found that surgery has improved 5-year survival, although Black patients experience worse mortality than their White counterparts.

The retrospective study used data associated with patients diagnosed with intrahepatic cholangiocarcinoma from the 18 Surveillance, Epidemiology, and End Results (SEER) Registry. The authors categorized patients into three groups based on the year of diagnosis, with 79.2% being White and 7.8% being Black. Nearly half the population was older than age 70. The numbers of male and female patients were also nearly equal, at 7,053 and 6,833, respectively.

The authors found that intrahepatic cholangiocarcinoma age-adjusted incidence rates increased from 0.6 per 100,000 in 2000 to 1.1 per 100,000 in 2017. The risk of intrahepatic cholangiocarcinoma diagnosis increased by 80% from 2000 to 2011. The cumulative annual percent change in intrahepatic cholangiocarcinoma incidence rate was 5.7% from 2000 to 2017. The researchers reported White men to be at greater risk than women and Black individuals. The Black population was found to have a 17% lower risk compared with White and Asian populations. The group also looked at survival statistics, finding overall survival at 12, 36, and 60 months to be 36.3%, 12.8%, and 8.1%, respectively. However, the risk of mortality was reduced by 64% after lymph node resection.

Disclosure: The study authors reported no conflicts of interest.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.